Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

SELL
$3.31 - $18.51 $923 - $5,164
-279 Reduced 38.01%
455 $1.93 Million
Q4 2023

Jan 12, 2024

BUY
$4.48 - $10.11 $3,288 - $7,420
734 New
734 $7.06 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Fortitude Family Office, LLC Portfolio

Follow Fortitude Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortitude Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortitude Family Office, LLC with notifications on news.